Comparison of Tumour-Specific Phenotypes in Human Primary and Expandable Pancreatic Cancer Cell Lines.
RNA-Seq
chemosensitivity
chemotherapy
patient-tailored therapy
regression analysis
statistical comparison of populations
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
31 Aug 2023
31 Aug 2023
Historique:
received:
26
06
2023
revised:
02
08
2023
accepted:
11
08
2023
medline:
11
9
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
epublish
Résumé
There is an ongoing need for patient-specific chemotherapy for pancreatic cancer. Tumour cells isolated from human tissues can be used to predict patients' response to chemotherapy. However, the isolation and maintenance of pancreatic cancer cells is challenging because these cells become highly vulnerable after losing the tumour microenvironment. Therefore, we investigated whether the cells retained their original characteristics after lentiviral transfection and expansion. Three human primary pancreatic cancer cell lines were lentivirally transduced to create expandable (Ex) cells which were then compared with primary (Pri) cells. No obvious differences in the morphology or epithelial-mesenchymal transition (EMT) were observed between the primary and expandable cell lines. The two expandable cell lines showed higher proliferation rates in the 2D and 3D models. All three expandable cell lines showed attenuated migratory ability. Differences in gene expression between primary and expandable cell lines were then compared using RNA-Seq data. Potential target drugs were predicted by differentially expressed genes (DEGs), and differentially expressed pathways (DEPs) related to tumour-specific characteristics such as proliferation, migration, EMT, drug resistance, and reactive oxygen species (ROS) were investigated using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. We found that the two expandable cell lines expressed similar chemosensitivity and redox-regulatory capability to gemcitabine and oxaliplatin in the 2D model as compared to their counterparts. In conclusion, we successfully generated expandable primary pancreatic cancer cell lines using lentiviral transduction. These expandable cells not only retain some tumour-specific biological traits of primary cells but also show an ongoing proliferative capacity, thereby yielding sufficient material for drug response assays, which may provide a patient-specific platform for chemotherapy drug screening.
Identifiants
pubmed: 37686338
pii: ijms241713530
doi: 10.3390/ijms241713530
pmc: PMC10488093
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Free Radic Biol Med. 2001 Jun 1;30(11):1191-212
pubmed: 11368918
Mol Ther Oncolytics. 2020 Oct 10;19:197-207
pubmed: 33251332
Bioinformatics. 2016 Sep 15;32(18):2847-9
pubmed: 27207943
Dig Dis Sci. 2014 Jul;59(7):1452-60
pubmed: 24532253
Int J Oncol. 2017 Apr;50(4):1352-1362
pubmed: 28259973
Biol Chem. 2013 Dec;394(12):1637-48
pubmed: 23863696
Theranostics. 2018 May 11;8(12):3224-3236
pubmed: 29930725
Anticancer Res. 2019 Jul;39(7):3317-3321
pubmed: 31262852
Cancer Manag Res. 2020 Jan 29;12:641-651
pubmed: 32099461
Mol Cancer. 2014 Jan 27;13:15
pubmed: 24468059
Biotechnol Appl Biochem. 2018 Sep;65(5):665-671
pubmed: 29575133
PLoS One. 2020 Jan 8;15(1):e0227454
pubmed: 31914150
Nat Commun. 2018 Mar 8;9(1):994
pubmed: 29520052
Biomed Pharmacother. 2017 Oct;94:1101-1110
pubmed: 28821161
Sci Rep. 2013 Dec 10;3:3462
pubmed: 24322507
Biochem Biophys Res Commun. 2009 Oct 9;388(1):96-101
pubmed: 19646419
AAPS J. 2013 Jul;15(3):816-31
pubmed: 23605950
Nat Chem Biol. 2011 Jul 18;7(8):504-11
pubmed: 21769097
Nucleic Acids Res. 2021 Jan 8;49(D1):D1144-D1151
pubmed: 33237278
Chem Sci. 2020 Feb 25;11(12):3215-3222
pubmed: 34122827
Sci Rep. 2018 Dec 17;8(1):17914
pubmed: 30559409
Oncol Rep. 2013 Mar;29(3):1124-32
pubmed: 23292285
Photosynth Res. 2005 Dec;86(3):435-57
pubmed: 16315075
Toxicol Appl Pharmacol. 1972 Jun;22(2):241-51
pubmed: 5048054
J Surg Res. 2010 May 1;160(1):90-101
pubmed: 19560785
BMC Bioinformatics. 2016 Jan 20;17:45
pubmed: 26791995
PLoS One. 2012;7(7):e40812
pubmed: 22815829
Assay Drug Dev Technol. 2011 Apr;9(2):108-24
pubmed: 21186936
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Cancer Res. 2000 Oct 1;60(19):5451-5
pubmed: 11034087
Nature. 1983 Aug 18-24;304(5927):596-602
pubmed: 6308472
Nat Biotechnol. 2016 May;34(5):525-7
pubmed: 27043002
Oncol Rep. 2013 Jun;29(6):2401-7
pubmed: 23563640
FASEB J. 2003 Jan;17(1):64-6
pubmed: 12424221
Tumour Biol. 2014 Oct;35(10):9683-91
pubmed: 24969558
Sci Rep. 2019 Jan 30;9(1):978
pubmed: 30700740
Int J Cancer. 2010 Jan 1;126(1):303-4
pubmed: 19859913
J Exp Clin Cancer Res. 2010 Aug 05;29:104
pubmed: 20684793
Cell Physiol Biochem. 2018;50(3):1201-1215
pubmed: 30355942
Front Oncol. 2020 Sep 15;10:1482
pubmed: 33042794
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Cancer Biol Ther. 2012 Oct;13(12):1205-13
pubmed: 22892843
Nat Cell Biol. 2010 Oct;12(10):924-5
pubmed: 20885418
PLoS One. 2008 Jun 04;3(6):e2372
pubmed: 18523635
Sci Rep. 2016 Jan 11;6:19103
pubmed: 26752500
Cells. 2019 Jan 05;8(1):
pubmed: 30621293
J Microsc. 2008 Aug;231(2):299-316
pubmed: 18778428
Am J Physiol. 1998 Dec;275(6):C1640-52
pubmed: 9843726
Oncol Rep. 2016 Mar;35(3):1718-26
pubmed: 26707376
Int J Oncol. 2015 Sep;47(3):857-66
pubmed: 26134824
Oncogene. 2020 May;39(20):3997-4013
pubmed: 32242147
J Surg Res. 2012 Jan;172(1):29-39
pubmed: 21683373
Nat Methods. 2008 Jun;5(6):553-9
pubmed: 18469822
Biochim Biophys Acta. 1973 Sep 26;314(3):372-81
pubmed: 4751237
Mol Cell Biol. 1986 Jun;6(6):1917-25
pubmed: 3785184
Mol Oncol. 2018 Apr;12(4):529-544
pubmed: 29453806
BMC Bioinformatics. 2016 Sep 20;17:388
pubmed: 27650223
J Neurochem. 2010 Sep;114(6):1590-604
pubmed: 20626554
Radiat Oncol. 2013 Nov 01;8:257
pubmed: 24180359
Cancer Res. 2008 Mar 1;68(5):1443-50
pubmed: 18316608
Front Pharmacol. 2017 Dec 22;8:936
pubmed: 29311937
BMC Biol. 2012 Mar 22;10:29
pubmed: 22439642
Radiat Res. 2008 Mar;169(3):301-10
pubmed: 18302483
Biotechnol Adv. 2016 Dec;34(8):1427-1441
pubmed: 27845258
Cancer Lett. 2017 Aug 28;402:213-224
pubmed: 28602977
Cancer Res. 2015 Sep 1;75(17):3529-42
pubmed: 26330165
Biomed Res Int. 2014;2014:546353
pubmed: 24812621
Int J Cancer. 2019 Sep 15;145(6):1570-1584
pubmed: 30834519
Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1770-1782
pubmed: 29510195
J Cell Biochem. 2020 Jan;121(1):632-641
pubmed: 31452251
Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G899-905
pubmed: 18239055
Cancer Res. 2009 Jul 15;69(14):5876-84
pubmed: 19605406
Trends Biotechnol. 2013 Jun;31(6):347-54
pubmed: 23597659
Biochim Biophys Acta Gen Subj. 2017 Feb;1861(2):296-306
pubmed: 27750041
Lab Invest. 2016 Dec;96(12):1268-1278
pubmed: 27775688
Cancer Discov. 2018 Sep;8(9):1112-1129
pubmed: 29853643
Oncol Rep. 2013 Sep;30(3):1223-30
pubmed: 23817566
Int J Biochem Cell Biol. 2019 Aug;113:17-26
pubmed: 31163263
Oxid Med Cell Longev. 2016;2016:1616781
pubmed: 26881012
J Gastrointest Surg. 2016 Jan;20(1):13-23; discussion 23-4
pubmed: 26503259
Anticancer Res. 2014 Dec;34(12):7077-90
pubmed: 25503135
Cancer. 2006 May 15;106(10):2284-94
pubmed: 16604531
Oncol Rep. 2014 Oct;32(4):1451-8
pubmed: 25070659
Curr Opin Cell Biol. 2005 Oct;17(5):559-64
pubmed: 16098726
Cell Cycle. 2012 Jul 15;11(14):2756-61
pubmed: 22767154
Cell Death Dis. 2018 May 10;9(5):538
pubmed: 29749405
Cell Biosci. 2021 Aug 4;11(1):154
pubmed: 34348789
Lab Invest. 2013 Jul;93(7):844-54
pubmed: 23752129
Cancer Gene Ther. 2009 Nov;16(11):841-7
pubmed: 19444305
Curr Oncol Rep. 2013 Apr;15(2):182-9
pubmed: 23341367
J Gastrointest Surg. 2010 Feb;14(2):252-60
pubmed: 20013316
J Transl Med. 2012 Apr 02;10:68
pubmed: 22472349
Pancreatology. 2013 Mar-Apr;13(2):140-6
pubmed: 23561972
Front Oncol. 2020 May 12;10:554
pubmed: 32477926
Nutrients. 2019 Apr 01;11(4):
pubmed: 30939781
Acta Pharm Sin B. 2020 Aug;10(8):1360-1381
pubmed: 32963937
Pancreas. 2013 Jul;42(5):813-8
pubmed: 23429495
Oncol Rep. 2016 Oct;36(4):2245-51
pubmed: 27572503
Cytometry A. 2003 Oct;55(2):119-25
pubmed: 14505317
PLoS One. 2016 May 13;11(5):e0155264
pubmed: 27175782
Oncol Rep. 2018 Aug;40(2):1093-1102
pubmed: 29845201
Hum Gene Ther. 2002 May 1;13(7):803-13
pubmed: 11975847
Cancer Metastasis Rev. 2013 Dec;32(3-4):391-402
pubmed: 23595307
J Natl Cancer Inst. 2013 Apr 3;105(7):452-8
pubmed: 23434901
Mol Cancer. 2016 Feb 24;15:18
pubmed: 26905733
Naunyn Schmiedebergs Arch Pharmacol. 2015 Jun;388(6):623-34
pubmed: 25743573
J Cell Sci. 2012 Dec 1;125(Pt 23):5591-6
pubmed: 23420197
Cancer Sci. 2008 Sep;99(9):1859-64
pubmed: 18691340
Exp Cell Res. 1961 Dec;25:585-621
pubmed: 13905658
Nat Rev Urol. 2013 Aug;10(8):483-7
pubmed: 23752995